Merck & Co. says it will settle a spate of lawsuits that blame the drugmaker’s blockbuster Gardasil cancer vaccine for ...
Merck (NYSE:MRK) has agreed to a settlement worth more than $50m to resolve over 200 lawsuits related to its Gardasil HPV ...
Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...
More biopharma layoffs are hitting New Jersey, this time from Merck & Co.in the latest phase of headcount reductions ...
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
Morning Overview on MSN
Intismeran autogene plus Keytruda dropped melanoma recurrence by close to 50% over five years in a Moderna-Merck-NYU trial unveiled at ASCO
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside Keytruda saw their risk of disease ...
Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales ...
By Julie Steenhuysen CHICAGO, June 1 (Reuters) - Merck is in discussions with various global health authorities about making ...
The spokesperson said Merck continues to employ more than 8,000 people in New Jersey. Merck has several facilities in eastern ...
Merck will eliminate 88 jobs at its Rahway headquarters by September as part of a multiyear restructuring and cost-cutting ...
As New Jersey grapples with over 7,600 layoffs in 2026, major employers like Novartis and Merck are making difficult choices ...
Dr. Rasha Kelej Merck Foundation Chief Executive Officer (CEO) and African First Ladies release “Rays of Hope” Animation Film ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results